PVLA PALVELLA THERAPEUTICS INC NE revenue, earnings and financials
For the quarter ended June 30, 2026, PALVELLA THERAPEUTICS INC NE reported revenue of n/a, net income of −$21.9M and diluted EPS of −$1.52; for the fiscal year ended December 2025 revenue was n/a.
PVLA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$38.6M, net income −$41.7M (margin n/a), EPS −$3.71
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$14.1M, net income −$17.4M (margin n/a), EPS −$7.83
- Fiscal year ended Dec 2023: revenue $42.8M, gross profit n/a, operating income −$11.9M, net income $18.7M (margin 43.7%), EPS $2.17
- Fiscal year ended Dec 2022: revenue $25.9M, gross profit n/a, operating income −$43.5M, net income −$33.3M (margin -128.5%), EPS n/a
- Fiscal year ended Dec 2021: revenue $31.4M, gross profit n/a, operating income −$51.8M, net income −$45.7M (margin -145.6%), EPS −$0.71
PVLA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$21.9M, EPS −$1.52
- Quarter ended Mar 31, 2026: revenue n/a, net income −$15.8M, EPS −$1.20
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$12.7M, EPS −$1.08
- Quarter ended Sep 30, 2025: revenue n/a, net income −$11.3M, EPS −$1.03
- Quarter ended Jun 30, 2025: revenue n/a, net income −$9.47M, EPS −$0.86
- Quarter ended Mar 31, 2025: revenue n/a, net income −$8.19M, EPS −$0.74
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$3.95M, EPS $0.12
- Quarter ended Sep 30, 2024: revenue $0 (down 100.0% year over year), net income −$6.78M, EPS −$3.94
- Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$4.17M, EPS −$2.47
- Quarter ended Mar 31, 2024: revenue $53.0K (down 97.3% year over year), net income −$2.54M, EPS −$1.54
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.30M (down 77.8% year over year), net income $38.7M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $19.5M (up 263.5% year over year), net income −$10.8M, EPS −$8.70
- Quarter ended Jun 30, 2023: revenue $20.1M (up 442.3% year over year), net income $3.98M, EPS $3.62
- Quarter ended Mar 31, 2023: revenue $1.94M (down 82.4% year over year), net income −$13.2M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $5.85M (down 30.8% year over year), net income −$8.10M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $5.37M (up 32.4% year over year), net income −$9.74M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $3.70M (up 12.6% year over year), net income −$10.3M, EPS −$0.14
- Quarter ended Mar 31, 2022: revenue $11.0M (down 29.7% year over year), net income −$5.10M, EPS −$0.07
- Quarter ended Dec 31, 2021 (from the annual report): revenue $8.44M, net income −$9.53M, EPS −$0.15
- Quarter ended Sep 30, 2021: revenue $4.06M, net income −$16.5M, EPS −$0.24
PVLA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$25.0M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$10.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$13.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$59.9M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$7.66M, share buybacks n/a
PVLA balance sheet
- Jun 30, 2026: cash $188M, total assets $254M, total liabilities $36.6M, shareholders' equity $217M
- Mar 31, 2026: cash $206M, total assets $264M, total liabilities $31.4M, shareholders' equity $232M
- Dec 31, 2025: cash $58.0M, total assets $59.6M, total liabilities $31.6M, shareholders' equity $28.0M
- Sep 30, 2025: cash $63.6M, total assets $66.9M, total liabilities $28.3M, shareholders' equity $38.7M
- Jun 30, 2025: cash $70.4M, total assets $73.7M, total liabilities $26.0M, shareholders' equity $47.8M
- Mar 31, 2025: cash $75.6M, total assets $79.4M, total liabilities $23.9M, shareholders' equity $55.6M
- Dec 31, 2024: cash $83.6M, total assets $88.2M, total liabilities $25.6M, shareholders' equity $62.6M
- Sep 30, 2024: cash $19.4M, total assets $20.5M, total liabilities n/a, shareholders' equity −$87.4M
Is PVLA profitable?
No. PALVELLA THERAPEUTICS INC NE lost $61.7M over the last four quarters.
What is PVLA's EPS?
Diluted earnings per share over the last four quarters were −$4.83; −$1.52 in the latest quarter.